Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Datetime
Upcoming First
Relevance
Session Number
Session Datetime
Novartis - Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future
(ID 112)
Time
08:45 - 10:15
Pfizer Oncology - Expert Perspectives in ALK+NSCLC: a round table discussion
(ID 110)
Time
08:45 - 09:45
MSD - Implementation of Immunotherapy in the First-Line Treatment of Esophageal, Gastroesophageal Junction and Gastric Cancers
(ID 113)
Time
08:45 - 10:15
MSD - Transforming the Adjuvant Treatment Paradigm in Melanoma
(ID 111)
Time
08:45 - 10:15
Pfizer Oncology - Complex Management of Relapsed and Refractory Multiple Myeloma (RRMM) and Evaluation of Unmet Needs
(ID 117)
Time
10:30 - 12:00
Amgen - Precision therapy in NSCLC: the dawn of KRAS G12C inhibition
(ID 115)
Time
10:30 - 12:00
Seagen - Navigating a new era in HER2+ metastatic breast cancer: Focus on HER2CLIMB
(ID 116)
Time
10:30 - 12:00
Pfizer Oncology - Confidence and clarity in advanced breast cancer: Insights from the real world
(ID 114)
Time
10:30 - 12:00
Takeda - Illuminating the Path Forward in EGFR Exon20 Insertion+ mNSCLC: Unmet Needs and the Evolving Treatment Landscape
(ID 121)
Time
18:45 - 20:15
Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies
(ID 118)
Time
18:45 - 20:15
Janssen - Expanding horizons for the targeted management of EGFR-Positive NSCLC
(ID 119)
Time
18:45 - 20:15
Bristol Myers Squibb - Latest advances in Muscle Invasive Urothelial Carcinoma: How Will They Impact Our Daily Practice?
(ID 123)
Time
08:45 - 09:55